Chang Matthew S, Nguyen Mindie H
Division of Gastroenterology and Hepatology, Stanford University Medical Center, 300 Pasteur Drive, Palo Alto, CA 94304, USA.
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):239-247. doi: 10.1016/j.bpg.2017.05.008. Epub 2017 Jun 6.
Hepatitis B virus (HBV) is a major cause of morbidity and mortality with a disproportionate impact on Asia and Africa. Current guidelines recommend screening at-risk populations for chronic HBV infection so that diagnosed individuals can be linked to appropriate hepatitis care. The vast majority of infected individuals are undiagnosed and untreated, and are at risk of developing cirrhosis, liver failure, and hepatocellular carcinoma. In individuals who are not yet infected, the HBV vaccine is safe and highly effective at preventing disease transmission. Countries with successful vaccination programs have been able to dramatically reduce their HBV prevalence. A concerted effort to screen, treat, and vaccinate at-risk individuals has the potential to eliminate HBV as a public health threat by 2030.
乙型肝炎病毒(HBV)是发病和死亡的主要原因,对亚洲和非洲的影响尤为严重。当前指南建议对高危人群进行慢性HBV感染筛查,以便确诊个体能够获得适当的肝炎护理。绝大多数感染者未被诊断和治疗,有发展为肝硬化、肝衰竭和肝细胞癌的风险。对于尚未感染的个体,HBV疫苗在预防疾病传播方面安全且高效。实施成功疫苗接种计划的国家已能够大幅降低其HBV流行率。齐心协力对高危个体进行筛查、治疗和接种疫苗,有可能到2030年消除HBV这一公共卫生威胁。